Drug Loading and Release: Development and Characterization of a Novel Therapeutic Agent-Nanographene Conjugate.

ABSTRACT: Compound 8, (5Z)-2-hydroxy-4-methyl-6-oxo-5-[(5-phenylfuran-2-yl)methylidene]-5,6-dihydropyridine-3-carbonitrile, is an effective NEK6 kinase inhibitor with demonstrated anticancer and neuroprotective activity. However, its poor aqueous solubility (3 μg/mL) presents a significant barrier to therapeutic development. To address this limitation, we developed a graphene-based nanocarrier system by conjugating compound 8 and its fluorinated derivatives (8-F and 8-CF₃) onto structurally uniform few-layer graphene nanoparticles (GNPs) obtained via ball-milling and liquid-phase exfoliation (B60). The resulting conjugates (8@B60, 8-F@B60, and 8-CF₃@B60) were thoroughly characterized by UV-vis, IR, and Raman

SUBMITTER: Hu K 

PROVIDER: S-EPMC12434661 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature